Key result
Antiplatelet agents, including aspirin, ticlopidine, and emerging GPIIb/IIIa inhibitors, are important therapeutic options for the prevention and treatment of vaso-occlusive thrombosis.
The review summarizes the role of existing antiplatelet agents like aspirin and ticlopidine while highlighting the development of more potent GPIIb/IIIa inhibitors for thrombosis.
Answers are grounded in this paper and cite their sources.
Supports antiplatelet options in thrombosis; leaves open comparative efficacy of emerging GPIIb/IIIa inhibitors.
Platelets contribute significantly to vaso-occlusive thrombosis, one of the major causes of death and disease throughout the world. Consequently, inhibiting platelet function is a potentially important therapeutic goal. Increasing evidence indicates the value of aspirin, a relatively weak antiplatelet agent in the prophylaxis and treatment of vascular disease, and of ticlopidine, a somewhat more potent antiplatelet agent that may be somewhat more effective clinically. Recent advances in our understanding of platelet physiology provide crucial information for the rational design of newer agents that can neutralize thrombin and block the platelet receptor most important in platelet aggregation (GPIIb/IIIa). Several such agents, which are much more potent than aspirin in vitro and in animal models of thrombosis, are now in human clinical trials.
No takes yet. Share an insight, caveat, or question.
Barry S. Coller (1992) conducted a review in Vaso-occlusive thrombosis. Antiplatelet agents (aspirin, ticlopidine, GPIIb/IIIa inhibitors) was evaluated. Antiplatelet agents, including aspirin, ticlopidine, and emerging GPIIb/IIIa inhibitors, are important therapeutic options for the prevention and treatment of vaso-occlusive thrombosis.
Synapse has enriched 10 related papers. Consider them for comparative context: